Product Portfolio

Single-Use Organ Preservation Devices

1. TEMPERATURE CONTROL

  • Ice storage results in excessive, uneven cooling
  • Ice storage results in temperatures near or below 0°C
  • SherpaPakTM and SherpaPerfusionTM maintain and monitor hypothermia between 4–8°C
  • SherpaPakTM and SherpaPerfusionTM provide temperatures readings of organ preservation solution

2. SPATIAL MANAGEMENT

  • Ice storage utilizes bags/tupperware containers not tested for organ use
  • Ice storage method results in organs touching bags/containers
  • SherpaPakTM and SherpaPerfusionTM fully immerse organ in solution via connector

3. REPLENISHING SOLUTION

  • In ice storage, organ ‘sits’ in same solution during preservation, while waste products accumulate and metabolites are consumed
  • SherpaPerfusionTM provides perfusion to replenish solution while maintaining solution constituents and pO2
© Bryce Vickmark. All rights reserved. www.vickmark.com 617.448.6758

SherpaPak™

Static Hypothermic Storage of Organs

  1. STANDARDIZE ORGAN PACKAGING
  2. MONITOR TEMPERATURE
  3. MONITOR TIME

 

  • SherpaPakTM Cardiac Transport System (CTS) is the first and only FDA-cleared heart transport device
  • Safe, consistent method for cold ischemic storage between 4 and 8°C
  • Single-use, fully disposable
  • FDA cleared for kidney and heart storage
  • Combined with any available cold storage solution that is FDA-cleared and effective for donor organ storage

*Patents issued and pending.

 

 

SherpaKit™

SherpaKit is Paragonix's Turnkey Solution

  • Combines the SherpaPak™ Transport Systems with commercially available and FDA-cleared organ preservation solutions
  • SherpaPak™ Cardiac Transport System plus any commercially available and FDA-cleared donor heart preservation solution
  • SherpaPak™ Kidney Transport System plus any commercially available and FDA-cleared donor kidney preservation solution
  • Convenient format, simplifying hospital purchasing and organ transport logistic management on a national level
  • Paragonix provides access to full spectrum of FDA cleared, commercially available organ preservation products
© Bryce Vickmark. All rights reserved. www.vickmark.com 617.448.6758

SherpaPerfusion™

Hypothermic Oxygenated Perfusion of Organs

  1. PULSATILE PERFUSION
  2. HOMOGENOUS COOLING
  3. pO2 MAINTENANCE

 

  • Homogenous cooling through the organ
  • Low pressure perfusion (between 4 and 6 mmHg)
  • Single-use device
  • Convenient snap-and-go mechanism

*Patents issued and pending.

**SherpaPerfusion is under development and is not cleared for sale.

SherpaTrak™

Real-time Tracking of Organs

  • Cloud based, national, multi-sensor, real-time tracking of solid donor organs
  • Accessible via powerful online portal

  • Combine with Sherpa™ platform

  • In alliance with international logistics Company

Consists of:

  • Sensing device

  • Web-based application

Real-time monitoring of:

  • Current location

  • Temperature

  • Light exposure (tampering)

  • Relative humidity

  • Barometric pressure

News & Publications

News

— 2014
October 27, 2014 - 

David D’Alessandro, MD, Joins as Medical Director

July 14, 2014 - 

Filing of a 510(k) Pre-market Notification with the US Food and Drug Administration for the Paragonix Sherpa Perfusion Cardiac Transport System

Publications

Heart, Lung and Vessels

In press

Innovative cold storage of donor organs using the Paragonix Sherpa Pak devices.

Michel SG, LaMuraglia GM, Madariaga ML, Anderson LM

Annals of Transplantation

2014 Aug 20; 19:409-16

Preservation of donor hearts using hypothermic oxygenated perfusion.

Michel SG, La Muraglia GM II, Madariaga ML, Titus JS, Selig MK, Farkash EA, Allan JS, Anderson LM, Madsen JC

ASAIO Journal

2013 Jul-Aug; 59(4):427-32

Oxygen consumption during oxygenated hypothermic perfusion as a measure of donor organ viability.

Bunegin L, Tolstykh GP, Gelineau JF, Cosimi AB, Anderson LM

Annals of Transplantation

2010 Jul-Sep; 15(3):35-43.

Novel portable hypothermic pulsatile perfusion preservation technology: Improved viability and function of rodent and canine kidneys.

Tolstykh GP, Gelineau JF, Maier LM, Bunegin L

Team

Management

Bill Edelman

Executive Chairman

Nearly 35 years of medical device industry experience, including executive positions at St Jude Medical, Baxter, TYRX and PolyTouch Medical; Chairman of the Board for Vitathreads LLC, NewVert, Ltd., Highland Instruments, Inc., Medivalve, Ltd., and Cardioflow, Ltd.; CEO for ETView, Ltd., (TASE: ETVW)

Lisa M. Anderson, Ph.D.

Co-Founder, President and Chief Operating Officer

Previously VP at Seed One Ventures; various academic positions at University of Cambridge (UK), Broad Institute at Massachusetts Institute of Technology (Cambridge), Brigham & Women’s Hospital (Boston); Junior Faculty at Harvard Medical School

Richard Burtt

VP Business Development

35 years of medical device experience, including Andover Medical Industries, Medtronic, and Nomir Medical Technologies; Executive Chair at Advanced Aesthetic Technologies, Inc.; Managing Director of Value Added Strategies, LLC

Leonard A. R. Golding, MB, BS, FRACS, FRCS(C), FACC

Chief Medical Officer

Retired Staff Consultant in the Department of Biomedical Engineering at Cleveland Clinic; previously secondary appointment in the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic

David D’Alessandro, MD

Medical Director

Assistant Professor, Cardiovascular and Thoracic Surgery, and Surgical Director, Cardiac Transplantation, at Montefiore Medical Center

Board of Directors

Bill Edelman

Nearly 35 years of medical device industry experience, including executive positions at St Jude Medical, Baxter, TYRX and PolyTouch Medical; Chairman of the Board for Vitathreads LLC, NewVert, Ltd., Highland Instruments, Inc., Medivalve, Ltd., and Cardioflow, Ltd.; CEO for ETView, Ltd., (TASE: ETVW)

Lisa M. Anderson, Ph.D.

Previously VP at Seed One Ventures; various academic positions at University of Cambridge (UK), Broad Institute at Massachusetts Institute of Technology (Cambridge), Brigham & Women’s Hospital (Boston); Junior Faculty at Harvard Medical School.

Richard Burtt

35 years of medical device experience, including Andover Medical Industries, Medtronic, and Nomir Medical Technologies; Executive Chair at Advanced Aesthetic Technologies, Inc.; Managing Director of Value Added Strategies, LLC

Charles Hanor

IP litigation and patent trademark prosecution in Texas; adjunct professor at St. Mary’s University Law School; admitted to practice before the United States Supreme Court, Supreme Court of Texas, the United States Patent and Trademark Office and various United States district and circuit courts.

DeWitt Davenport

President and Trustee of Davenport Realty Trust, leading a diversified company based in Cape Cod, MA, with business interests located throughout New England; Trustee of Cape Cod Healthcare Inc., Eastern Bank and two family foundations; Director of Churchill Casualty Insurance and the Edward Bangs Kelley and Eliza Kelley Foundation, Inc. as well as Founder of the Seaside Le Mans – The Race for the Cape Cod Community

Scientific and Clinical Advisors

Abbas Ardehali, MD, FACS

Professor of Surgery and Medicine in the Division of Cardiothoracic Surgery and Director of the Heart , Lung and Heart-Lung Transplant Programs at The David Geffen School of Medicine at UCLA. Chief of Cardiac Surgery at The Greater Los Angeles VA Healthcare System.

Steven S. L. Tsui, MA, MD, FRCS

Director of Transplant & Mechanical Circulatory Support program at Papworth Hospital, Cambridge, UK. Deputy Chair of the Cardiothoracic Advisory Group at NHS Blood & Transplant, UK, and the East of England Deanery Training Program Director in Cardiothoracic Surgery.

Joren Madsen, MD, DPhil

Professor of Surgery at Harvard Medical School and the W. Gerald & Patricia R. Austen Distinguished Scholar in Cardiac Surgery at Massachusetts General Hospital (MGH); Director of the Transplant Center and co-director of the Transplantation Biology Research Center at MGH

Andreas Zuckermann, MD

Staff Surgeon in the Department of Cardiac Surgery and Director of Transplantation at Medical University of Vienna, Austria; previously Director fo the International Society for Heart and Lung Transplantation.

Stefan G. Tullius, MD, Ph.D.

Chief of Transplant Surgery at Brigham and Women’s Hospital in Boston; Associate Professor of Surgery at Harvard Medical School and Principal Investigator at the Transplant Surgery Research Laboratory at BWH.

Contact

Paragonix Technologies Inc.

c/o Vaughn & Associates
639 Granite Street
Braintree, MA02184, USA

Mail: lisa@paragonixtechnologies.com
Tel: +1 (617) 817 7790
Fax: +1 (617) 812 3057